Senate Hearing on Mylan (MYL) EpiPen Pricing Likely in the Works - Evercore ISI

August 24, 2016 2:00 PM EDT
Get Alerts MYL Hot Sheet
Price: $37.07 +0.93%

Rating Summary:
    12 Buy, 12 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 3 | Down: 5 | New: 17
Trade MYL Now!
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Evercore ISI Mylan (NASDAQ: MYL) analyst Umer Raffat points out that a Senate hearing is likely in the works on EpiPen pricing, based on commentary in today's letter written by Chairman and Ranking Member of Senate Aging Committee.

In the letter, Mylan is being asked to brief the Committee staff within 2 weeks.

"... hearing likely in the works it seems," he said.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Trader Talk

Related Entities

Umer Raffat

Add Your Comment